Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to build a database of results from a new test that measures contrast sensitivity (the Spaeth-Richman Contrast Sensitivity Test (SPARCS)). Contrast sensitivity is an important part of your ability to see. When contrast sensitivity decreases, you are less able to see objects and detect motion. For instance, if you have decreased contrast sensitivity, you might be less able to read, see in the dark, drive, hit a ball, or walk safely. Decrease in contrast sensitivity leads to a decrease in quality of life.


Clinical Trial Description

Objective: To build a normative database for the Spaeth / Richman Contrast Sensitivity Test (SPARCS).

Background: Patients with glaucoma have diminished contrast sensitivity. SPARCS is a novel test designed to determine the contrast threshold in the central 5 degrees of vision as well as each of the 4 peripheral quadrants (superotemporal, superonasal, inferotemporal, inferonasal). It is performed on a standard computer with at least 1024 x 768 monitor resolution. The correct testing distance is 50 cm away from the computer screen. Appropriate refractive correction is used. Testing is performed in a room with standardized lighting (85 cd / m2) and no windows in order to minimize glare and reflections. Testing is performed monocularly with the non-tested eye covered by an eye patch. The purpose of this study is to build a normative database for SPARCS.

Study Design: Cross sectional observational study.

Methods: Healthy volunteers will be recruited from the Wills Eye Institute after obtaining informed consent following the principles of the Helsinki Convention. Approximately 320 people free of ocular disease will be recruited to form a portion of the normative database for SPARCS. A goal of 20 subjects per decade of life (10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+) for both Caucasians and African Americans will be recruited. Other ethnicities will also be recruited, though without specific recruitment goals. Future study locations will help diversify the population of the normative database.

After agreeing to participate in the study, subjects will be assessed to determine if they qualify. Potential participants will be asked if they have any known eye diseases or decreased vision. Best-corrected monocular visual acuities will be assessed using an ETDRS visual acuity chart. A slit lamp examination will be performed to confirm good ocular health. Subjects will be excluded if they have any apparent ocular disease that affects visual acuity or visual function. For example, people with glaucoma, macular degeneration, or diabetic retinopathy will be excluded. Additional exclusion criteria includes: visual acuity 20/40 or worse; cataract grade 2 3+ or worse; posterior capsular opacity grade 2 3+ or worse; refractive error greater than +5 or -5 diopters; and incisional eye surgery within the prior 3 months.

After a person qualifies for the normative database, he or she will then take SPARCS. A trained technician will position the patient to the correct testing distance, check room lighting, and then explain the test. Subjects will be told to fixate on the central area and when ready, click the central area once with a computer mouse. Vertical dark bars will briefly appear in 1 of the 5 tested areas on the computer monitor. A subject will then move the mouse to the area the image appeared and click it once. When the subject is ready for the next image to appear, he or she will click again on the central area. Subjects are also instructed to guess where the image appeared if unsure. Vertical square waves of varying contrast levels will then continue to appear in a random pattern until threshold has been reached for each area. After the testing algorithm has been completed, the test will automatically end.

Each eye of an eligible subject will take the test twice after receiving instructions from a technician. The technician will remain in the testing room the first two times SPARCS is taken. A half hour later, the subject will then take SPARCS again without instructions from the technician and without the technician being present in the room.

The mean score and standard deviation of each area and the total score will be analyzed for age, gender, race, and lens status. Spearman correlations will be used to examine continuous variables and Kruskal-Wallis analysis for categorical measures. Test-retest repeatability will be assessed using the Coefficient of Repeatability and the Intraclass Correlation Coefficient. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02627339
Study type Observational [Patient Registry]
Source Wills Eye
Contact
Status Completed
Phase N/A
Start date August 2012
Completion date August 2015

See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A